文献速递造血干细胞移植与细胞治疗

伊布替尼治疗既往治疗失败的慢性移植物抗宿主病

Ibrutinib for chronic graft-versus-host disease after failure of prior therapy.
PubMed 文献 · Blood · 2017-09-18

这项多中心、开放标签研究评估伊布替尼治疗对含糖皮质激素治疗反应不佳的活动性慢性移植物抗宿主病(cGVHD)患者的安全性和疗效。42例既往1至3线治疗失败的患者接受伊布替尼420 mg每日一次治疗,中位随访13.9个月时最佳总缓解率为67%,71%的缓解者缓解持续≥20周;最常见不良事件为疲乏、腹泻、肌肉痉挛、恶心和瘀斑。基于这些结果,伊布替尼在美国获批用于成人cGVHD患者经1线或以上全身治疗失败后的治疗。

要点

  • 42例既往1至3线治疗失败的cGVHD患者接受伊布替尼420 mg每日一次,中位随访13.9个月时最佳总缓解率为67%。
  • 71%的缓解者缓解持续≥20周,多个cGVHD器官受累的患者多数获得多器官缓解。
  • 缓解者中位糖皮质激素剂量从基线0.29 mg/kg每日降至第49周0.12 mg/kg每日,5例缓解者停用糖皮质激素。

核心结论

  • 伊布替尼在既往至少1线治疗的cGVHD患者中产生有临床意义的缓解且安全性可接受;基于这些结果,伊布替尼在美国获批用于成人cGVHD患者经1线或以上全身治疗失败后的治疗。

研究设计与样本

  • 多中心、开放标签研究,纳入42例对含糖皮质激素治疗反应不佳的活动性cGVHD患者,患者既往1至3线治疗失败,接受伊布替尼420 mg每日一次直至cGVHD进展。
  • 主要疗效终点为依据2005年美国国立卫生研究院(NIH)标准的cGVHD缓解。

主要发现

  • 中位随访13.9个月时最佳总缓解率为67%,71%的缓解者缓解持续≥20周。
  • 在所评估的受累器官中均观察到缓解,多数多个cGVHD器官受累的患者获得多器官缓解。
  • 缓解者中位糖皮质激素剂量从基线0.29 mg/kg每日降至第49周0.12 mg/kg每日,5例缓解者停用糖皮质激素。
  • 最常见不良事件为疲乏、腹泻、肌肉痉挛、恶心和瘀斑。
  • 与炎症、纤维化和cGVHD相关的可溶性因子血浆水平随伊布替尼治疗随时间显著下降。

关键数值与推荐

  • 伊布替尼剂量为420 mg每日一次,直至cGVHD进展。
  • 疗效评估依据2005年美国国立卫生研究院(NIH)标准。
  • 试验注册号为NCT02195869。

临床怎么用

  • 基于该研究结果,伊布替尼在美国获批用于成人cGVHD患者经1线或以上全身治疗失败后的治疗。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic graft-versus-host disease (cGVHD) is a serious complication of allogeneic stem cell transplantation with few effective options available after failure of corticosteroids. B and T cells play a role in the pathophysiology of cGVHD. Ibrutinib inhibits Bruton tyrosine kinase in B cells and interleukin-2-inducible T-cell kinase in T cells. In preclinical models, ibrutinib reduced severity of cGVHD. This multicenter, open-label study evaluated the safety and efficacy of ibrutinib in patients with active cGVHD with inadequate response to corticosteroid-containing therapies. Forty-two patients who had failed 1 to 3 prior treatments received ibrutinib (420 mg) daily until cGVHD progression. The primary efficacy end point was cGVHD response based on 2005 National Institutes of Health criteria. At a median follow-up of 13.9 months, best overall response was 67%; 71% of responders showed a sustained response for ≥20 weeks. Responses were observed across involved organs evaluated. Most patients with multiple cGVHD organ involvement had a multiorgan response. Median corticosteroid dose in responders decreased from 0.29 mg/kg per day at baseline to 0.12 mg/kg per day at week 49; 5 responders discontinued corticosteroids. The most common adverse events were fatigue, diarrhea, muscle spasms, nausea, and bruising. Plasma levels of soluble factors associated with inflammation, fibrosis, and cGVHD significantly decreased over time with ibrutinib. Ibrutinib resulted in clinically meaningful responses with acceptable safety in patients with ≥1 prior treatments for cGVHD. Based on these results, ibrutinib was approved in the United States for treatment of adult patients with cGVHD after failure of 1 or more lines of systemic therapy. This trial was registered at www.clinicaltrials.gov as #NCT02195869.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Miklos D, Cutler CS, Arora M, et al. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood. 2017. PMID: 28924018. doi:10.1182/blood-2017-07-793786

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。